Related Experiment Video

Updated: May 29, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting Axl and Mer kinases in cancer

Anupam Verma1, Steven L Warner, Hariprasad Vankayalapati

  • 1Pediatric Hematology/Oncology, Primary Children's Medical Center, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA. anupam.verma@hsc.utah.edu

Molecular Cancer Therapeutics
|September 22, 2011
PubMed

Insights

Receptor tyrosine kinases (RTKs) like Axl and Mer are crucial in cancer cell survival. Inhibiting these kinases may offer a new therapeutic strategy to improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Receptor tyrosine kinases (RTKs) regulate vital cellular processes.
  • The TAM RTK family (Tyro-3, Axl, Mer) is implicated in human cancers.
  • Growth arrest-specific gene 6 (Gas6) is a key ligand for TAM RTKs.

Purpose of the Study:

  • To review the role of Axl and Mer in normal cellular function and oncogenesis.
  • To explore the therapeutic potential of inhibiting Axl and Mer in cancer treatment.

Main Methods:

  • Literature review of existing studies on Axl, Mer, and their ligand Gas6.
  • Analysis of the role of TAM RTKs in cancer cell proliferation and survival.
  • Evaluation of Axl and Mer as potential therapeutic targets.

Main Results:

  • Overexpression of TAM receptors is observed in various human cancers.
  • Gas6 binding to Axl and Mer promotes cancer cell proliferation and survival.
  • Inhibition of Axl and Mer can sensitize cancer cells to cytotoxic agents.

Conclusions:

  • Axl and Mer play significant roles in cancer development and progression.
  • Targeting Axl and Mer presents a promising therapeutic strategy for cancer treatment.
  • Further research into Axl and Mer inhibition could lead to novel cancer therapies.

More Related Videos

Identification of Kinase-substrate Pairs Using High Throughput Screening11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...